Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors
Funding was provided by CytoImmune Therapeutics and grants from the National Cancer Institute (CA266457, CA033572, and CA210087).
Authors
- Hans Meisen
- Joycelynne Palmer (ORCID: https://orcid.org/0000-0001-6480-7557)
- Timothy W. Synold (ORCID: https://orcid.org/0000-0002-4075-2544)
- Miguel A. Villalona‐Calero (ORCID: https://orcid.org/0000-0002-1991-5070)
- Stephen J. Forman (ORCID: https://orcid.org/0000-0002-2803-4152)
- Xiaochen Li (ORCID: https://orcid.org/0000-0002-2558-954X)
- Michael A. Caligiuri (ORCID: https://orcid.org/0000-0002-4095-3020)
- Jeffrey VanDeusen (ORCID: https://orcid.org/0000-0002-4171-5649)
- Ivone Bruno
- Colt A. Egelston (ORCID: https://orcid.org/0000-0001-8440-1271)
- Omer I. Butt
- Lei Tian (ORCID: https://orcid.org/0000-0002-4039-4820)
- Lei Zhang (ORCID: https://orcid.org/0009-0008-9783-092X)
- Jianhua Yu
- Eliezer Romeu-Bonilla
- Claudia Aceves
- Catherine Cortez
Institutions
- City Of Hope National Medical Center (US)
- University of California, Irvine (US)
- Florida Hospital Cancer Institute (US)
- Comprehensive Cancer Center Vienna (AT)
- Biologie Computationnelle, Quantitative et Synthétique (FR)
- Aimmune Therapeutics (United Kingdom) (GB)
- Quantitative BioSciences (US)
- DecImmune Therapeutics (United States) (US)
- Ionic Systems (United States) (US)
- Netherlands Comprehensive Cancer Organisation (NL)
- The Japanese Data Center for Hematopoietic Cell Transplantation (JP)
Publication Details
- Journal
- JCI Insight
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1172/jci.insight.186890
- Citations
- 8
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- University of California, Irvine
- National Cancer Institute
- Chao Family Comprehensive Cancer Center